Misonix, Inc. is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic and maxillo-facial surgery. The Company's wound team markets and sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company's history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients.
Company profile
Ticker
MSON
Exchange
Website
CEO
Stavros G. Vizirgianakis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Misonix OpCo, Inc. • Solsys Medical, LLC ...
IRS number
112148932
MSON stock data
Latest filings (excl ownership)
RW
Registration withdrawal request
22 Nov 21
15-12B
Securities registration termination
8 Nov 21
8-K
Termination of a Material Definitive Agreement
29 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Oct 21
Transcripts
MSON
Earnings call transcript
2021 Q3
9 May 21
MSON
Earnings call transcript
2021 Q2
5 Feb 21
MSON
Earnings call transcript
2021 Q1
8 Nov 20
MSON
Earnings call transcript
2020 Q4
3 Sep 20
MSON
Earnings call transcript
2020 Q3
12 May 20
MSON
Earnings call transcript
2020 Q2
5 Feb 20
MSON
Earnings call transcript
2020 Q1
10 Nov 19
MSON
Earnings call transcript
2019 Q4
14 Aug 19
MSON
Earnings call transcript
2019 Q3
12 May 19
MSON
Earnings call transcript
2019 Q2
6 Feb 19
Latest ownership filings
Financial summary
Quarter (USD) | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 21 | Jun 20 | Jun 19 | Jun 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.05 mm | 31.05 mm | 31.05 mm | 31.05 mm | 31.05 mm | 31.05 mm |
Cash burn (monthly) | (no burn) | 577.74 k | 1.45 mm | 1.20 mm | 706.22 k | 748.95 k |
Cash used (since last report) | n/a | 19.44 mm | 48.70 mm | 40.22 mm | 23.77 mm | 25.21 mm |
Cash remaining | n/a | 11.60 mm | -17.65 mm | -9.17 mm | 7.28 mm | 5.84 mm |
Runway (months of cash) | n/a | 20.1 | -12.2 | -7.7 | 10.3 | 7.8 |
Institutional ownership, Q4 2021
19.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 69 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 42.35 mm |
Total shares | 3.39 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
1315 Capital | 1.69 mm | $21.18 mm |
SVLSF Vi | 1.69 mm | $21.18 mm |